What is Resverlogix?
Founded in 2001 and headquartered in Calgary, Alberta, Canada, Resverlogix is dedicated to advancing apabetalone (RVX-208), a selective bromodomain and extra-terminal inhibitor. The company is currently in Phase III clinical trials, investigating apabetalone's efficacy across a spectrum of serious conditions including cardiovascular diseases, end-stage renal disease, chronic kidney disease, neurodegenerative disorders, Fabry disease, peripheral artery disease, and diabetes mellitus. This focus on complex, multi-faceted diseases positions Resverlogix as a key player in therapeutic innovation.
How much funding has Resverlogix raised?
Resverlogix has raised a total of $264M across 13 funding rounds:
Unspecified
$1.8M
Share Placement
$1.7M
Debt
$30M
Share Placement
$36.6M
Share Placement
$10M
Share Placement
$87M
Debt
$30M
Share Placement
$10.3M
Multiple Rounds
$32.2M
Debt
$6M
Unspecified (2011): $1.8M, investors not publicly disclosed
Share Placement (2014): $1.7M supported by NGN BioMed Opportunity II, L.P.
Debt (2014): $30M featuring Citibank
Share Placement (2015): $36.6M backed by Shenzhen Hepalink Pharmaceutical Co., Ltd. and Eastern Capital Limited
Share Placement (2017): $10M with participation from Eastern Capital Limited and Shenzhen Hepalink Pharmaceutical Co., Ltd
Share Placement (2017): $87M led by Shenzhen Hepalink Pharmaceutical Co. Ltd.
Debt (2018): $30M supported by Third Eye Capital
Share Placement (2018): $10.3M, investors not publicly disclosed
Share Placement (2019): $5M backed by Shenzhen Hepalink Pharmaceutical Co. Ltd.
Stock Issuance/Offering (2019): $15.2M, investors not publicly disclosed
Debt (2019): $12M, investors not publicly disclosed
Debt (2021): $6M supported by Shenzhen Hepalink Pharmaceutical Group Co.
Key Investors in Resverlogix
Shenzhen Hepalink Pharmaceutical Co., Ltd
Shenzhen Hepalink Pharmaceutical Co., Ltd is a significant player in the pharmaceutical industry, likely focusing on drug development and manufacturing, and has provided backing to Resverlogix's clinical stage assets.
Eastern Capital Limited
Eastern Capital Limited is an investment entity that has participated in Resverlogix's funding rounds, suggesting a strategic interest in the biotechnology sector.
Third Eye Capital
Third Eye Capital has provided debt financing to Resverlogix, indicating a role in supporting the company's operational and developmental capital needs.
What's next for Resverlogix?
The substantial capital raised, particularly the recent strategic investment, indicates a strong vote of confidence from investors in Resverlogix's clinical pipeline and therapeutic approach. This financing is expected to fuel the progression of apabetalone through its late-stage trials, potentially paving the way for regulatory submissions and eventual market entry. The company's strategic partnerships and ongoing research efforts will be critical in navigating the path to commercialization and addressing unmet medical needs in its target disease areas.
See full Resverlogix company page
